DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Hofman MS, Emmett L, Sandhu SK. et al
TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).
J Clin Oncol 2020;
38
DOI: 10.1200/JCO.2020.38.15_suppl.5500. (suppl; abstr 5500)
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.